NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Sponsor: Eli Lilly and Company. Phase: PHASE3. Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis